Entering text into the input field will update the search result below

Enrollment completed in Jazz Pharma's late-stage study of JZP-110; shares off 7% after hours

Nov. 28, 2016 5:30 PM ETJazz Pharmaceuticals plc (JAZZ) StockBy: Douglas W. House, SA News Editor6 Comments
  • Jazz Pharmaceuticals (NASDAQ:JAZZ) is down 7% after hours on light volume on the heels of the company's announcement that enrollment is now complete in its 240-subject Phase 3 clinical trial assessing JZP-110 for the treatment of excessive sleepiness (ES) associated with narcolepsy. Top-line data are expected in Q2 2017.
  • Top-line results in another Phase 3 assessing JZP-110 for the treatment of ES in obstructive sleep apnea should be available in Q1 2017.
  • JZP-110 is a selective dopamine and norepinephrine reuptake inhibitor. It has Orphan Drug status in the U.S. for narcolepsy.

Recommended For You

About JAZZ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
JAZZ--
Jazz Pharmaceuticals plc